<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 21 Mar 2025 20:12:23 +0000</lastbuilddate>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reviving the Swan: Presenting the Chicago Hemodynamic Forum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 21:e012725. doi: 10.1161/CIRCHEARTFAILURE.124.012725. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40116016</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.012725>10.1161/CIRCHEARTFAILURE.124.012725</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116016</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mark N Belkin</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Ryan J Tedford</dc:creator>
<dc:creator>Jonathan Grinstein</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>Reviving the Swan: Presenting the Chicago Hemodynamic Forum</dc:title>
<dc:identifier>pmid:40116016</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.012725</dc:identifier>
</item>
<item>
<title>3D Echocardiographic and CMR Imaging for the Assessment of Right Ventricular Function and Tricuspid Regurgitation Severity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: 3DE provides an accurate assessment of TR severity comparable to CMR. The proposed 5-class grading scheme for TR severity using CMR demonstrates high accuracy and external validity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017638. doi: 10.1161/CIRCIMAGING.124.017638. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tricuspid regurgitation (TR) is associated with increased mortality and is often underdiagnosed due to limitations in imaging modalities. While routine 2-dimensional echocardiography (2DE) demonstrates frequent disagreement with cardiac magnetic resonance imaging (CMR) in classifying TR severity, the incremental value of 3-dimensional echocardiography (3DE) remains unknown also due to the lack of a generalizable grading scheme across imaging modalities. Therefore, this study provides an intermodality comparison of all 3 imaging modalities (2DE, 3DE, and CMR) in evaluating TR severity and proposes an adapted 5-class grading scheme for TR severity using CMR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 144 patients with symptomatic TR were analyzed across 2 cohorts: a derivation cohort (n=91) from the University Hospital of Munich and a validation cohort (n=53) from the Heart Center Leipzig. All patients underwent multimodality imaging, including transthoracic 2DE, transesophageal 3DE, and CMR. The adapted 5-class CMR-based grading scheme was proposed and externally validated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the derivation cohort (median age 81 years, 66% female), TR severity grading by 3DE highly correlated with CMR (87% concordance within a 1-grade difference), significantly outperforming 2DE (68% concordance). While 3DE underestimated RV dimensions compared with CMR (<i>P</i>&lt;0.001), it provided a comparable measure of TR severity and RV function. 2DE achieved the lowest accuracy rates compared with CMR (34.5%; <i>P</i>=0.005) with frequent overestimation of TR severity. An overestimation of TR severity by 3DE compared with CMR was significantly less frequent than with 2DE (21% versus 56%; <i>P</i>&lt;0.001). Cohen κ analysis confirmed a substantial and superior agreement between 3DE and CMR compared with 2DE (κ=0.63 versus 0.41; <i>P</i>=0.01). The results were externally validated, showing comparable results within the derivation and validation cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: 3DE provides an accurate assessment of TR severity comparable to CMR. The proposed 5-class grading scheme for TR severity using CMR demonstrates high accuracy and external validity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40116010</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017638>10.1161/CIRCIMAGING.124.017638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116010</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Philipp M Doldi</dc:creator>
<dc:creator>Ludwig T Weckbach</dc:creator>
<dc:creator>Nicola Fink</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Cecilia Ennin</dc:creator>
<dc:creator>Julien Dinkel</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Christian Besler</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>3D Echocardiographic and CMR Imaging for the Assessment of Right Ventricular Function and Tricuspid Regurgitation Severity</dc:title>
<dc:identifier>pmid:40116010</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017638</dc:identifier>
</item>
<item>
<title>Severe Mitral Regurgitation in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Severe MR in paradoxical low-flow, low-gradient severe aortic stenosis is associated with adverse outcomes and distinctive left ventricular remodeling. Aortic valve replacement improves survival across all MR grades, with greater impact in severe MR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017598. doi: 10.1161/CIRCIMAGING.124.017598. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Severe mitral regurgitation (MR) also causes a low-flow state, adding complexity to diagnosis and management. This study aimed to examine the impact of severe MR on outcomes in paradoxical low-flow, low-gradient severe aortic stenosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from an institutional echo database identified 1189 patients with adjudicated severe aortic stenosis (aortic valve area ≤1.0 cm<sup>2</sup>), low transaortic gradients (mean gradient &lt;40 mm Hg), preserved left ventricular ejection fraction (≥50%), and low-flow rate (Q ≤210 mL/s) to confirm paradoxical low-flow, low-gradient severe aortic stenosis. Subgroups were based on MR severity (severe and nonsevere). Clinical outcomes included all-cause mortality, aortic valve replacement, heart failure hospitalizations, and a composite outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the severe MR group (n=80), patients had lower flow rates, increased left ventricular dimensions, and a more eccentric hypertrophy pattern compared with nonsevere MR (n=1109). Over a follow-up of up to 5 years, severe MR correlated with higher all-cause mortality (<i>P</i>=0.02) and aortic valve replacement rates (<i>P</i>=0.012). After adjustment, severe MR was independently associated with increased all-cause mortality risk (hazard ratio, 1.43; <i>P</i>=0.011) and composite outcome (hazard ratio, 1.64; <i>P</i>&lt;0.001). Aortic valve replacement significantly reduced mortality at every MR degree, with the most substantial impact in severe MR (hazard ratio, 0.18; <i>P</i>&lt;0.001). Propensity-adjusted models demonstrated a stronger aortic valve replacement impact with increasing MR degree (<i>P</i><sub>interaction</sub>=0.044).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Severe MR in paradoxical low-flow, low-gradient severe aortic stenosis is associated with adverse outcomes and distinctive left ventricular remodeling. Aortic valve replacement improves survival across all MR grades, with greater impact in severe MR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40116009</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017598>10.1161/CIRCIMAGING.124.017598</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116009</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shani Dahan</dc:creator>
<dc:creator>Jacob Dal-Bianco</dc:creator>
<dc:creator>Ygal Plakht</dc:creator>
<dc:creator>Mayooran Namasivayam</dc:creator>
<dc:creator>Romain Capoulade</dc:creator>
<dc:creator>Xin Zeng</dc:creator>
<dc:creator>Jonathan J Passeri</dc:creator>
<dc:creator>Evin Yucel</dc:creator>
<dc:creator>Michael H Picard</dc:creator>
<dc:creator>Robert A Levine</dc:creator>
<dc:creator>Judy Hung</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Severe Mitral Regurgitation in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis</dc:title>
<dc:identifier>pmid:40116009</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017598</dc:identifier>
</item>
<item>
<title>CT Predictors of Epicardial Coronary Spasm in Patients With Angina and Nonobstructive Coronary Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with nonobstructive coronary arteries, a prespasm provocation test using a noninvasive comprehensive assessment with CCTA may help identify those at high risk for VSA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017565. doi: 10.1161/CIRCIMAGING.124.017565. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Recent studies have shown that vasospastic angina (VSA) is associated with myocardial bridge (MB) and pericoronary adipose tissue inflammation. We aimed to investigate the clinical and coronary computed tomography angiographic (CCTA) features that could predict VSA in patients with angina and nonobstructive coronary arteries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We retrospectively studied patients with nonobstructive coronary arteries who underwent a spasm provocation test and CCTA within 3 months before the spasm provocation test. Pericoronary adipose tissue inflammation was evaluated using the fat attenuation index (FAI) of the proximal reference diameter and the inner 2 mm adipose tissue layer (FAI<sub>2mm</sub>) from the vessel wall. Coronary plaques were qualitatively classified as noncalcified or calcified plaques in each vessel. In addition, MB was evaluated in the left descending artery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 142 patients, with 55 (38.7%) diagnosed with VSA. Factors associated with VSA included male sex (74.5% versus 51.7%, <i>P</i>=0.01), smoking history (70.9% versus 52.9%, <i>P</i>=0.05), CCTA-defined MB (49.1% versus 28.7%, <i>P</i>=0.02), and FAI, especially FAI<sub>2mm</sub> in the right coronary artery-FAI<sub>2mm</sub> (-68.8 Hounsfield unit versus -74.0 Hounsfield unit, <i>P</i>&lt;0.01), as well as the presence of CCTA-defined mixed or noncalcified plaque anywhere in the coronary tree (65.5% versus 39.1%, <i>P</i>&lt;0.01). In a multivariable analysis, CCTA-defined MB (odds ratio, 2.23 [95% CI, 1.03-4.83]; <i>P</i>=0.04), right coronary artery-FAI<sub>2mm</sub> (odds ratio, 1.07 [95% CI, 1.02-1.12]; <i>P</i>&lt;0.01), and the presence of mixed or noncalcified plaque (odds ratio, 3.15 [95% CI, 1.45-6.80]; <i>P</i>&lt;0.01) were independently associated with VSA. A combination of CCTA-defined MB in the left descending artery, high right coronary artery-FAI<sub>2mm</sub> (≥-72.6 Hounsfield unit, median), and CCTA-defined mixed or noncalcified plaque in the coronary tree predicted VSA with a 75.0% probability, while the absence of all 3 factors precluded VSA with 95.6% probability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with nonobstructive coronary arteries, a prespasm provocation test using a noninvasive comprehensive assessment with CCTA may help identify those at high risk for VSA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40116006</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017565>10.1161/CIRCIMAGING.124.017565</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116006</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Takashi Mineo</dc:creator>
<dc:creator>Eisuke Usui</dc:creator>
<dc:creator>Yoshihisa Kanaji</dc:creator>
<dc:creator>Masahiro Hada</dc:creator>
<dc:creator>Tatsuhiro Nagamine</dc:creator>
<dc:creator>Hiroki Ueno</dc:creator>
<dc:creator>Kai Nogami</dc:creator>
<dc:creator>Mirei Setoguchi</dc:creator>
<dc:creator>Tomohiro Tahara</dc:creator>
<dc:creator>Tatsuya Sakamoto</dc:creator>
<dc:creator>Masahiro Hoshino</dc:creator>
<dc:creator>Tomoyo Sugiyama</dc:creator>
<dc:creator>Taishi Yonetsu</dc:creator>
<dc:creator>Tetsuo Sasano</dc:creator>
<dc:creator>Tsunekazu Kakuta</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>CT Predictors of Epicardial Coronary Spasm in Patients With Angina and Nonobstructive Coronary Arteries</dc:title>
<dc:identifier>pmid:40116006</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017565</dc:identifier>
</item>
<item>
<title>MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with ATTRwt-CM and prolonged T2, MRI-ECV did not accurately reflect histological amyloid load. Our findings underscore the need for a multiparametric imaging approach, combining both ECV and T2 mapping, to better characterize myocardial tissue in patients with ATTRwt-CM, and further prospective research in larger and more diverse cohorts is needed to validate our results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017427. doi: 10.1161/CIRCIMAGING.124.017427. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: MRI-derived myocardial extracellular volume fraction (ECV) is elevated in the presence of fibrosis, amyloid deposition, inflammation and edema. In patients with cardiac amyloidosis and prolonged T2 due to concomitant inflammation or edema, MRI-ECV may not correctly reflect histological amyloid load. The authors sought to determine whether MRI-ECV can accurately reflect histological amyloid load in 2 groups of patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), with and without T2 prolongation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This retrospective study included consecutive patients with ATTRwt-CM who underwent endomyocardial biopsy and cardiac MRI from March 2017 to October 2021 for initial evaluation of ATTRwt-CM. We measured MRI-ECV and T2, and evaluated correlation between MRI-ECV and amyloid load from endomyocardial biopsy by means of Pearson correlation analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 44 patients (mean age, 75±6 years [SD]; 40 men), 24 showed T2 prolongation (T2≥50 milliseconds). All specimens obtained by endomyocardial biopsy were suitable for analysis. The interval between endomyocardial biopsy and cardiac MRI examination was a median of 3 days (interquartile range, 2-4). In the absence of T2 prolongation due to increased water content, MRI-ECV and amyloid load showed a moderately significant correlation (Spearman ρ=0.50, <i>P</i>=0.03). However, in the presence of T2 prolongation, there was no significant correlation between MRI-ECV and amyloid load (Spearman ρ=-0.05, <i>P</i>=0.83).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with ATTRwt-CM and prolonged T2, MRI-ECV did not accurately reflect histological amyloid load. Our findings underscore the need for a multiparametric imaging approach, combining both ECV and T2 mapping, to better characterize myocardial tissue in patients with ATTRwt-CM, and further prospective research in larger and more diverse cohorts is needed to validate our results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40116000</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017427>10.1161/CIRCIMAGING.124.017427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116000</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Masafumi Kidoh</dc:creator>
<dc:creator>Seitaro Oda</dc:creator>
<dc:creator>Seiji Takashio</dc:creator>
<dc:creator>Mami Morioka</dc:creator>
<dc:creator>Naoto Kuyama</dc:creator>
<dc:creator>Tetsuya Oguni</dc:creator>
<dc:creator>Takeshi Nakaura</dc:creator>
<dc:creator>Yasunori Nagayama</dc:creator>
<dc:creator>Yasuhiro Izumiya</dc:creator>
<dc:creator>Kenichi Tsujita</dc:creator>
<dc:creator>Toshinori Hirai</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping</dc:title>
<dc:identifier>pmid:40116000</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017427</dc:identifier>
</item>
<item>
<title>Physical Activity Reduction in Patients Following ICD Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115999/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Arrhythm Electrophysiol. 2025 Mar 21:e013196. doi: 10.1161/CIRCEP.124.013196. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115999/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115999</a> | DOI:<a href=https://doi.org/10.1161/CIRCEP.124.013196>10.1161/CIRCEP.124.013196</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115999</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael Christof</dc:creator>
<dc:creator>Alex Page</dc:creator>
<dc:creator>Spencer Rosero</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Arrhythmia and electrophysiology</dc:source>
<dc:title>Physical Activity Reduction in Patients Following ICD Therapy</dc:title>
<dc:identifier>pmid:40115999</dc:identifier>
<dc:identifier>doi:10.1161/CIRCEP.124.013196</dc:identifier>
</item>
<item>
<title>Performance of AlphaMissense and Other In Silico Predictors to Determine Pathogenicity of Missense Variants in Sarcomeric Genes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Genom Precis Med. 2025 Mar 21:e004922. doi: 10.1161/CIRCGEN.124.004922. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115995</a> | DOI:<a href=https://doi.org/10.1161/CIRCGEN.124.004922>10.1161/CIRCGEN.124.004922</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115995</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mario Ruiz</dc:creator>
<dc:creator>Juan Pablo Ochoa</dc:creator>
<dc:creator>Candela Migoyo-Bettoni</dc:creator>
<dc:creator>Jorge de la Barrera</dc:creator>
<dc:creator>Alba Delrio-Lorenzo</dc:creator>
<dc:creator>Manuel A Fernández-Rojo</dc:creator>
<dc:creator>Ines Martinez-Martin</dc:creator>
<dc:creator>Jorge Alegre-Cebollada</dc:creator>
<dc:creator>Enrique Lara-Pezzi</dc:creator>
<dc:creator>Fatima Sanchez-Cabo</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Genomic and precision medicine</dc:source>
<dc:title>Performance of AlphaMissense and Other In Silico Predictors to Determine Pathogenicity of Missense Variants in Sarcomeric Genes</dc:title>
<dc:identifier>pmid:40115995</dc:identifier>
<dc:identifier>doi:10.1161/CIRCGEN.124.004922</dc:identifier>
</item>
<item>
<title>National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>In 2014, the Organ Procurement and Transplant Network began reappraisal of the United States heart transplant allocation policy. Driven by ongoing discordance between organ supply and demand, high waitlist mortality, and increasing exception requests, the Thoracic Committee radically redesigned the priority scheme and drafted a 6-tiered algorithm, included durable device complications into policy, expanded broader sharing, and increased the number of mandatory listing variables to develop a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 21:e011631. doi: 10.1161/CIRCHEARTFAILURE.124.011631. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In 2014, the Organ Procurement and Transplant Network began reappraisal of the United States heart transplant allocation policy. Driven by ongoing discordance between organ supply and demand, high waitlist mortality, and increasing exception requests, the Thoracic Committee radically redesigned the priority scheme and drafted a 6-tiered algorithm, included durable device complications into policy, expanded broader sharing, and increased the number of mandatory listing variables to develop a future heart allocation score. This became the 2018 New Heart Allocation Policy. Changes in allocation priority have resulted in a significant increase in the use of temporary mechanical circulatory support in waitlisted candidates with a concomitant decrease in the number of patients bridged to transplanted with durable left ventricular assist device support. The number of exception requests continues to increase, particularly for patients listed status 2 and for multiorgan transplants. Importantly, fewer patients are being delisted for clinical improvement, suggesting missed opportunities for recovery. The current review will critically evaluate the 2018 heart allocation policy 6 years later, briefly focusing on the history of heart allocation in the United States, the current and evolving algorithms for candidate prioritization including continuous distribution, the impact of technology and innovation on transplant rates and future policy development, and the ongoing regulatory oversight and governance changes in the Organ Procurement and Transplant Network.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115988</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.011631>10.1161/CIRCHEARTFAILURE.124.011631</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115988</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lauren K Truby</dc:creator>
<dc:creator>Liviu Klein</dc:creator>
<dc:creator>Jane E Wilcox</dc:creator>
<dc:creator>Maryjane Farr</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later</dc:title>
<dc:identifier>pmid:40115988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.011631</dc:identifier>
</item>
<item>
<title>Postimplantation Size of WATCHMAN FLX Pro: A New Left Atrial Appendage Closure System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115980/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar 21:e015056. doi: 10.1161/CIRCINTERVENTIONS.124.015056. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115980/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115980</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.015056>10.1161/CIRCINTERVENTIONS.124.015056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115980</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tetsuma Kawaji</dc:creator>
<dc:creator>Shun Hojo</dc:creator>
<dc:creator>Ryota Takahashi</dc:creator>
<dc:creator>Masashi Kato</dc:creator>
<dc:creator>Takafumi Yokomatsu</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Postimplantation Size of WATCHMAN FLX Pro: A New Left Atrial Appendage Closure System</dc:title>
<dc:identifier>pmid:40115980</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.015056</dc:identifier>
</item>
<item>
<title>Multiregional Implementation Initiative's Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115978/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among healthcare systems participating in IMPLEMENT-HF, there was a marked increase in QMT use among eligible patients over the course of the initiative. This quality improvement initiative supports a learning collaborative model to promote improvements in QMT use.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 21:e012547. doi: 10.1161/CIRCHEARTFAILURE.124.012547. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite randomized data for survival benefit (with class 1 recommendations) for treating heart failure (HF) with reduced ejection fraction using quadruple medical therapy (QMT)-defined as evidence-based β-blockers, sodium-glucose cotransporter 2 inhibitor, preferably angiotensin receptor/neprilysin inhibitor, and mineralocorticoid receptor antagonist-it is underutilized. IMPLEMENT-HF is a multiregional HF quality improvement initiative to improve care and outcomes for patients with HF by enhancing the use of QMT in routine practice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This analysis of HF with reduced ejection fraction treatment in patients from hospitals participating in the American Heart Association's Get With The Guidelines-HF who volunteered to participate in IMPLEMENT-HF in 7 US regions. IMPLEMENT-HF included multidisciplinary learning to share strategies for formulary changes, electronic health record tools, and patient resources with site-level feedback reports. Participants gathered QMT data at discharge and 30 days after discharge. We evaluated QMT utilization and variation, in addition to other prespecified performance measures, from Q1 2021 to Q2 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median (interquartile range) age of 43 558 admitted patients at 61 hospitals was 74 (63-83) years; 16 530 (38%) belonged to racial and ethnic minorities, and 22 228 (51%) were women. Between Q1 2021 and Q2 2023, defect-free QMT improved from 4.7% to 44.6% at discharge and from 0% to 44.8% at 30 days (both <i>P</i>&lt;0.0001). There was also substantially improved incorporation of health-related social needs assessments. The magnitude of improvements was similar when stratified by sex or race and ethnicity, yet there was significant regional variation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among healthcare systems participating in IMPLEMENT-HF, there was a marked increase in QMT use among eligible patients over the course of the initiative. This quality improvement initiative supports a learning collaborative model to promote improvements in QMT use.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115978/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115978</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.012547>10.1161/CIRCHEARTFAILURE.124.012547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115978</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Chandler Beon</dc:creator>
<dc:creator>Sruthi Cherkur</dc:creator>
<dc:creator>Lynn Mallas-Serdynski</dc:creator>
<dc:creator>Kathie Thomas</dc:creator>
<dc:creator>John Spertus</dc:creator>
<dc:creator>Georges Chahoud</dc:creator>
<dc:creator>Kanika P Mody</dc:creator>
<dc:creator>Mitchell T Saltzberg</dc:creator>
<dc:creator>Lee R Goldberg</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Nancy Sweitzer</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Ileana Pina</dc:creator>
<dc:creator>Sara Paul</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Joyce Wald</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Mariell Jessup</dc:creator>
<dc:creator>Michelle Congdon</dc:creator>
<dc:creator>Robin Kiser</dc:creator>
<dc:creator>Clyde Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>Multiregional Implementation Initiative's Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF</dc:title>
<dc:identifier>pmid:40115978</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.012547</dc:identifier>
</item>
<item>
<title>Inflammatory Myofibroblastic Tumor Mimicking Pulmonary Artery Sarcoma and Causing Pulmonary Artery Obstruction: A Rare Case Report</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017658. doi: 10.1161/CIRCIMAGING.124.017658. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115977</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017658>10.1161/CIRCIMAGING.124.017658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115977</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pingping Han</dc:creator>
<dc:creator>Yanfen Shi</dc:creator>
<dc:creator>Huan Li</dc:creator>
<dc:creator>Liping Fu</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Inflammatory Myofibroblastic Tumor Mimicking Pulmonary Artery Sarcoma and Causing Pulmonary Artery Obstruction: A Rare Case Report</dc:title>
<dc:identifier>pmid:40115977</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017658</dc:identifier>
</item>
<item>
<title>(Doubts on) The Mechanistic Role of Pulmonary Veins Reconnection in Paroxysmal and Persistent Atrial Fibrillation: A Meta-Analysis of Mandatory Remapping Studies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Arrhythm Electrophysiol. 2025 Mar 21:e013456. doi: 10.1161/CIRCEP.124.013456. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115975</a> | DOI:<a href=https://doi.org/10.1161/CIRCEP.124.013456>10.1161/CIRCEP.124.013456</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115975</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Marco Bergonti</dc:creator>
<dc:creator>Tardu Özkartal</dc:creator>
<dc:creator>Maria Luce Caputo</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Arrhythmia and electrophysiology</dc:source>
<dc:title>(Doubts on) The Mechanistic Role of Pulmonary Veins Reconnection in Paroxysmal and Persistent Atrial Fibrillation: A Meta-Analysis of Mandatory Remapping Studies</dc:title>
<dc:identifier>pmid:40115975</dc:identifier>
<dc:identifier>doi:10.1161/CIRCEP.124.013456</dc:identifier>
</item>
<item>
<title>Pulsed field ablation for complex variant pulmonary vein and posterior wall isolation using the Varipulse catheter: a case report</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115621/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 3;9(3):ytaf107. doi: 10.1093/ehjcr/ytaf107. eCollection 2025 Mar.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115621/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115621</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11925008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">PMC11925008</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf107>10.1093/ehjcr/ytaf107</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115621</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sebastian E Beyer</dc:creator>
<dc:creator>Moneeb Khalaph</dc:creator>
<dc:creator>Thomas Fink</dc:creator>
<dc:creator>Christian Sohns</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Pulsed field ablation for complex variant pulmonary vein and posterior wall isolation using the Varipulse catheter: a case report</dc:title>
<dc:identifier>pmid:40115621</dc:identifier>
<dc:identifier>pmc:PMC11925008</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf107</dc:identifier>
</item>
<item>
<title>The hernia is mightier than the aorta</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 7;9(3):ytaf122. doi: 10.1093/ehjcr/ytaf122. eCollection 2025 Mar.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40115620</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11925006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">PMC11925006</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf122>10.1093/ehjcr/ytaf122</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115620</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Hisato Takagi</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>The hernia is mightier than the aorta</dc:title>
<dc:identifier>pmid:40115620</dc:identifier>
<dc:identifier>pmc:PMC11925006</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf122</dc:identifier>
</item>
<item>
<title>Could CT radiomics be the new frontier for myocardial tissue characterisation in cardiomyopathies?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40114425/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 21:jeaf096. doi: 10.1093/ehjci/jeaf096. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40114425/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40114425</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf096>10.1093/ehjci/jeaf096</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40114425</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Betty Raman</dc:creator>
<dc:creator>Nicholas Clarke</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Could CT radiomics be the new frontier for myocardial tissue characterisation in cardiomyopathies?</dc:title>
<dc:identifier>pmid:40114425</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf096</dc:identifier>
</item>
<item>
<title>T1 mapping is not ready to replace the use of contrast agents in stress CMR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40114389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 21:jeaf098. doi: 10.1093/ehjci/jeaf098. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40114389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40114389</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf098>10.1093/ehjci/jeaf098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40114389</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Giovanni Donato Aquaro</dc:creator>
<dc:creator>Carmelo De Gori</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>T1 mapping is not ready to replace the use of contrast agents in stress CMR</dc:title>
<dc:identifier>pmid:40114389</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf098</dc:identifier>
</item>
<item>
<title>Mitochondrial quality control in cardiomyocytes: safeguarding the heart against disease and ageing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40113864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>Mitochondria are multifunctional organelles that are important for many different cellular processes, including energy production and biosynthesis of fatty acids, haem and iron-sulfur clusters. Mitochondrial dysfunction leads to a disruption in these processes, the generation of excessive reactive oxygen species, and the activation of inflammatory and cell death pathways. The consequences of mitochondrial dysfunction are particularly harmful in energy-demanding organs such as the heart. Loss of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 20. doi: 10.1038/s41569-025-01142-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mitochondria are multifunctional organelles that are important for many different cellular processes, including energy production and biosynthesis of fatty acids, haem and iron-sulfur clusters. Mitochondrial dysfunction leads to a disruption in these processes, the generation of excessive reactive oxygen species, and the activation of inflammatory and cell death pathways. The consequences of mitochondrial dysfunction are particularly harmful in energy-demanding organs such as the heart. Loss of terminally differentiated cardiomyocytes leads to cardiac remodelling and a reduced ability to sustain contraction. Therefore, cardiomyocytes rely on multilayered mitochondrial quality control mechanisms to maintain a healthy population of mitochondria. Mitochondrial chaperones protect against protein misfolding and aggregation, and resident proteases eliminate damaged proteins through proteolysis. Irreparably damaged mitochondria can also be degraded through mitochondrial autophagy (mitophagy) or ejected from cells inside vesicles. The accumulation of dysfunctional mitochondria in cardiomyocytes is a hallmark of ageing and cardiovascular disease. This accumulation is driven by impaired mitochondrial quality control mechanisms and contributes to the development of heart failure. Therefore, there is a strong interest in developing therapies that directly target mitochondrial quality control in cardiomyocytes. In this Review, we discuss the current knowledge of the mechanisms involved in regulating mitochondrial quality in cardiomyocytes, how these pathways are altered with age and in disease, and the therapeutic potential of targeting mitochondrial quality control pathways in cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40113864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40113864</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01142-1>10.1038/s41569-025-01142-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40113864</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Rishith Ravindran</dc:creator>
<dc:creator>Åsa B Gustafsson</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Mitochondrial quality control in cardiomyocytes: safeguarding the heart against disease and ageing</dc:title>
<dc:identifier>pmid:40113864</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01142-1</dc:identifier>
</item>
<item>
<title>Apixaban outcomes in AF patients with single dose-reduction criterion: ASPIRE 1-year results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40113236/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: In Korean patients with AF meeting a single dose reduction criterion of apixaban, off-label reduced-dose apixaban showed no significant differences in SSE and major bleeding compared to the on-label standard dose. These findings suggest that individualized anticoagulation strategies, such as reduced dose apixaban, may be beneficial for patients with a high risk of bleeding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Pharmacother. 2025 Mar 20:pvaf018. doi: 10.1093/ehjcvp/pvaf018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIMS: This study, using a prospective cohort, evaluated the effectiveness and safety of off-label reduced-dose apixaban versus the on-label dose in atrial fibrillation (AF) patients meeting a single dose reduction criterion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: The efficAcy and Safety of aPixaban In Real-world practice in Korean frail patients with AF (ASPIRE) study is a multicenter, prospective observational cohort involving AF patients who met a single dose reduction criterion of apixaban. Patients were divided into two groups: on-label standard dose (5 mg twice daily) and off-label reduced dose (2.5 mg twice daily). The primary effectiveness outcome was stroke/systemic embolism (SSE), and the primary safety outcome was major bleeding. Of 1 944 patients (mean age 74.3 ± 7.9 years, 56% women), 997 (51%) were receiving off-label reduced dose apixaban. The off-label reduced dose group was older, had more comorbidities, higher concomitant antiplatelet use, and higher CHA2DS2-VASc and HAS-BLED scores. During follow-up (1.0 ± 0.2 year), crude incidence rates were 0.9 vs. 0.7 per 100 person-years for SSE and 0.5 vs. 1.0 for major bleeding in the on-label vs. off-label groups. After inverse probability of treatment weighting, the off-label reduced dose group showed no significant differences in the risk of SSE (HR 0.67, 95% CI 0.28-1.59, p = 0.370) and major bleeding (HR 1.38, 95% CI 0.44-4.35, p = 0.578) compared to the on-label standard dose group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: In Korean patients with AF meeting a single dose reduction criterion of apixaban, off-label reduced-dose apixaban showed no significant differences in SSE and major bleeding compared to the on-label standard dose. These findings suggest that individualized anticoagulation strategies, such as reduced dose apixaban, may be beneficial for patients with a high risk of bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40113236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40113236</a> | DOI:<a href=https://doi.org/10.1093/ehjcvp/pvaf018>10.1093/ehjcvp/pvaf018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40113236</guid>
<pubDate>Thu, 20 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>So-Ryoung Lee</dc:creator>
<dc:creator>JungMin Choi</dc:creator>
<dc:creator>Soonil Kwon</dc:creator>
<dc:creator>Hyo-Jeong Ahn</dc:creator>
<dc:creator>Kyung-Yeon Lee</dc:creator>
<dc:creator>Jong-Il Choi</dc:creator>
<dc:creator>Sung Ho Lee</dc:creator>
<dc:creator>Jung Ho Heo</dc:creator>
<dc:creator>Il-Young Oh</dc:creator>
<dc:creator>Young Keun On</dc:creator>
<dc:creator>Hee Tae Yu</dc:creator>
<dc:creator>Kwang-No Lee</dc:creator>
<dc:creator>Nam-Ho Kim</dc:creator>
<dc:creator>Hyung Wook Park</dc:creator>
<dc:creator>Ki Hong Lee</dc:creator>
<dc:creator>Seung Yong Shin</dc:creator>
<dc:creator>Hyoung-Seob Park</dc:creator>
<dc:creator>Seongwook Han</dc:creator>
<dc:creator>Seil Oh</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Jong-Sung Park</dc:creator>
<dc:creator>Eue-Keun Choi</dc:creator>
<dc:date>2025-03-20</dc:date>
<dc:source>European heart journal. Cardiovascular pharmacotherapy</dc:source>
<dc:title>Apixaban outcomes in AF patients with single dose-reduction criterion: ASPIRE 1-year results</dc:title>
<dc:identifier>pmid:40113236</dc:identifier>
<dc:identifier>doi:10.1093/ehjcvp/pvaf018</dc:identifier>
</item>
<item>
<title>Growth of the maternal intestine during reproduction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40112802/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>The organs of many female animals are remodeled by reproduction. Using the mouse intestine, a striking and tractable model of organ resizing, we find that reproductive remodeling is anticipatory and distinct from diet- or microbiota-induced resizing. Reproductive remodeling involves partially irreversible elongation of the small intestine and fully reversible growth of its epithelial villi, associated with an expansion of isthmus progenitors and accelerated enterocyte migration. We identify...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 14:S0092-8674(25)00200-4. doi: 10.1016/j.cell.2025.02.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The organs of many female animals are remodeled by reproduction. Using the mouse intestine, a striking and tractable model of organ resizing, we find that reproductive remodeling is anticipatory and distinct from diet- or microbiota-induced resizing. Reproductive remodeling involves partially irreversible elongation of the small intestine and fully reversible growth of its epithelial villi, associated with an expansion of isthmus progenitors and accelerated enterocyte migration. We identify induction of the SGLT3a transporter in a subset of enterocytes as an early reproductive hallmark. Electrophysiological and genetic interrogations indicate that SGLT3a does not sustain digestive functions or enterocyte health; rather, it detects protons and sodium to extrinsically support the expansion of adjacent Fgfbp1-positive isthmus progenitors, promoting villus growth. Our findings reveal unanticipated specificity to physiological organ remodeling. We suggest that organ- and state-specific growth programs could be leveraged to improve pregnancy outcomes or prevent maladaptive consequences of such growth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40112802/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40112802</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.015>10.1016/j.cell.2025.02.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40112802</guid>
<pubDate>Thu, 20 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tomotsune Ameku</dc:creator>
<dc:creator>Anna Laddach</dc:creator>
<dc:creator>Hannah Beckwith</dc:creator>
<dc:creator>Alexandra Milona</dc:creator>
<dc:creator>Loranzie S Rogers</dc:creator>
<dc:creator>Cornelia Schwayer</dc:creator>
<dc:creator>Emma Nye</dc:creator>
<dc:creator>Iain R Tough</dc:creator>
<dc:creator>Jean-Louis Thoumas</dc:creator>
<dc:creator>Umesh Kumar Gautam</dc:creator>
<dc:creator>Yi-Fang Wang</dc:creator>
<dc:creator>Shreya Jha</dc:creator>
<dc:creator>Alvaro Castano-Medina</dc:creator>
<dc:creator>Christopher Amourda</dc:creator>
<dc:creator>Patric M Vaelli</dc:creator>
<dc:creator>Sira Gevers</dc:creator>
<dc:creator>Elaine E Irvine</dc:creator>
<dc:creator>Leah Meyer</dc:creator>
<dc:creator>Ivan Andrew</dc:creator>
<dc:creator>Ka Lok Choi</dc:creator>
<dc:creator>Bhavik Patel</dc:creator>
<dc:creator>Alice J Francis</dc:creator>
<dc:creator>Chris Studd</dc:creator>
<dc:creator>Laurence Game</dc:creator>
<dc:creator>George Young</dc:creator>
<dc:creator>Kevin G Murphy</dc:creator>
<dc:creator>Bryn Owen</dc:creator>
<dc:creator>Dominic J Withers</dc:creator>
<dc:creator>Maria Rodriguez-Colman</dc:creator>
<dc:creator>Helen M Cox</dc:creator>
<dc:creator>Prisca Liberali</dc:creator>
<dc:creator>Martin Schwarzer</dc:creator>
<dc:creator>François Leulier</dc:creator>
<dc:creator>Vassilis Pachnis</dc:creator>
<dc:creator>Nicholas W Bellono</dc:creator>
<dc:creator>Irene Miguel-Aliaga</dc:creator>
<dc:date>2025-03-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Growth of the maternal intestine during reproduction</dc:title>
<dc:identifier>pmid:40112802</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.015</dc:identifier>
</item>
<item>
<title>Asian diversity in human immune cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40112801/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>The relationships of human diversity with biomedical phenotypes are pervasive yet remain understudied, particularly in a single-cell genomics context. Here, we present the Asian Immune Diversity Atlas (AIDA), a multi-national single-cell RNA sequencing (scRNA-seq) healthy reference atlas of human immune cells. AIDA comprises 1,265,624 circulating immune cells from 619 donors, spanning 7 population groups across 5 Asian countries, and 6 controls. Though population groups are frequently compared...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 18:S0092-8674(25)00202-8. doi: 10.1016/j.cell.2025.02.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The relationships of human diversity with biomedical phenotypes are pervasive yet remain understudied, particularly in a single-cell genomics context. Here, we present the Asian Immune Diversity Atlas (AIDA), a multi-national single-cell RNA sequencing (scRNA-seq) healthy reference atlas of human immune cells. AIDA comprises 1,265,624 circulating immune cells from 619 donors, spanning 7 population groups across 5 Asian countries, and 6 controls. Though population groups are frequently compared at the continental level, we found that sub-continental diversity, age, and sex pervasively impacted cellular and molecular properties of immune cells. These included differential abundance of cell neighborhoods as well as cell populations and genes relevant to disease risk, pathogenesis, and diagnostics. We discovered functional genetic variants influencing cell-type-specific gene expression, which were under-represented in non-Asian populations, and helped contextualize disease-associated variants. AIDA enables analyses of multi-ancestry disease datasets and facilitates the development of precision medicine efforts in Asia and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40112801/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40112801</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.017>10.1016/j.cell.2025.02.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40112801</guid>
<pubDate>Thu, 20 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kian Hong Kock</dc:creator>
<dc:creator>Le Min Tan</dc:creator>
<dc:creator>Kyung Yeon Han</dc:creator>
<dc:creator>Yoshinari Ando</dc:creator>
<dc:creator>Damita Jevapatarakul</dc:creator>
<dc:creator>Ankita Chatterjee</dc:creator>
<dc:creator>Quy Xiao Xuan Lin</dc:creator>
<dc:creator>Eliora Violain Buyamin</dc:creator>
<dc:creator>Radhika Sonthalia</dc:creator>
<dc:creator>Deepa Rajagopalan</dc:creator>
<dc:creator>Yoshihiko Tomofuji</dc:creator>
<dc:creator>Shvetha Sankaran</dc:creator>
<dc:creator>Mi-So Park</dc:creator>
<dc:creator>Mai Abe</dc:creator>
<dc:creator>Juthamard Chantaraamporn</dc:creator>
<dc:creator>Seiko Furukawa</dc:creator>
<dc:creator>Supratim Ghosh</dc:creator>
<dc:creator>Gyo Inoue</dc:creator>
<dc:creator>Miki Kojima</dc:creator>
<dc:creator>Tsukasa Kouno</dc:creator>
<dc:creator>Jinyeong Lim</dc:creator>
<dc:creator>Keiko Myouzen</dc:creator>
<dc:creator>Sarintip Nguantad</dc:creator>
<dc:creator>Jin-Mi Oh</dc:creator>
<dc:creator>Nirmala Arul Rayan</dc:creator>
<dc:creator>Sumanta Sarkar</dc:creator>
<dc:creator>Akari Suzuki</dc:creator>
<dc:creator>Narita Thungsatianpun</dc:creator>
<dc:creator>Prasanna Nori Venkatesh</dc:creator>
<dc:creator>Jonathan Moody</dc:creator>
<dc:creator>Masahiro Nakano</dc:creator>
<dc:creator>Ziyue Chen</dc:creator>
<dc:creator>Chi Tian</dc:creator>
<dc:creator>Yuntian Zhang</dc:creator>
<dc:creator>Yihan Tong</dc:creator>
<dc:creator>Crystal T Y Tan</dc:creator>
<dc:creator>Anteneh Mehari Tizazu</dc:creator>
<dc:creator>Marie Loh</dc:creator>
<dc:creator>You Yi Hwang</dc:creator>
<dc:creator>Roger C Ho</dc:creator>
<dc:creator>Anis Larbi</dc:creator>
<dc:creator>Tze Pin Ng</dc:creator>
<dc:creator>Hong-Hee Won</dc:creator>
<dc:creator>Fred A Wright</dc:creator>
<dc:creator>Alexandra-Chloé Villani</dc:creator>
<dc:creator>Jong-Eun Park</dc:creator>
<dc:creator>Murim Choi</dc:creator>
<dc:creator>Boxiang Liu</dc:creator>
<dc:creator>Arindam Maitra</dc:creator>
<dc:creator>Manop Pithukpakorn</dc:creator>
<dc:creator>Bhoom Suktitipat</dc:creator>
<dc:creator>Kazuyoshi Ishigaki</dc:creator>
<dc:creator>Yukinori Okada</dc:creator>
<dc:creator>Kazuhiko Yamamoto</dc:creator>
<dc:creator>Piero Carninci</dc:creator>
<dc:creator>John C Chambers</dc:creator>
<dc:creator>Chung-Chau Hon</dc:creator>
<dc:creator>Ponpan Matangkasombut</dc:creator>
<dc:creator>Varodom Charoensawan</dc:creator>
<dc:creator>Partha P Majumder</dc:creator>
<dc:creator>Jay W Shin</dc:creator>
<dc:creator>Woong-Yang Park</dc:creator>
<dc:creator>Shyam Prabhakar</dc:creator>
<dc:date>2025-03-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Asian diversity in human immune cells</dc:title>
<dc:identifier>pmid:40112801</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.017</dc:identifier>
</item>
<item>
<title>Jumbo phage killer immune system targets early infection of nucleus-forming phages</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40112800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250321161221&amp;v=2.18.0.post9+e462414
      <description>Jumbo bacteriophages of the ϕKZ-like family assemble a lipid-based early phage infection (EPI) vesicle and a proteinaceous nucleus-like structure during infection. These structures protect the phage from nucleases and may create selective pressure for immunity mechanisms targeting this specific phage family. Here, we identify "jumbo phage killer" (Juk), a two-component immune system that terminates infection of ϕKZ-like phages, suppressing the expression of early phage genes and preventing phage...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 18:S0092-8674(25)00201-6. doi: 10.1016/j.cell.2025.02.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Jumbo bacteriophages of the ϕKZ-like family assemble a lipid-based early phage infection (EPI) vesicle and a proteinaceous nucleus-like structure during infection. These structures protect the phage from nucleases and may create selective pressure for immunity mechanisms targeting this specific phage family. Here, we identify "jumbo phage killer" (Juk), a two-component immune system that terminates infection of ϕKZ-like phages, suppressing the expression of early phage genes and preventing phage DNA replication and phage nucleus assembly while saving the cell. JukA (formerly YaaW) rapidly senses the EPI vesicle by binding to an early-expressed phage protein, gp241, and then directly recruits JukB. The JukB effector structurally resembles a pore-forming toxin and destabilizes the EPI vesicle. Functional anti-ϕKZ JukA homologs are found across bacterial phyla, associated with diverse effectors. These findings reveal a widespread defense system that specifically targets early events executed by ϕKZ-like jumbo phages prior to phage nucleus assembly.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40112800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250321161221&v=2.18.0.post9+e462414">40112800</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.016>10.1016/j.cell.2025.02.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40112800</guid>
<pubDate>Thu, 20 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Li Yuping</dc:creator>
<dc:creator>Linlin Guan</dc:creator>
<dc:creator>Isabelle Becher</dc:creator>
<dc:creator>Kira S Makarova</dc:creator>
<dc:creator>Xueli Cao</dc:creator>
<dc:creator>Surabhi Hareendranath</dc:creator>
<dc:creator>Jingwen Guan</dc:creator>
<dc:creator>Frank Stein</dc:creator>
<dc:creator>Siqi Yang</dc:creator>
<dc:creator>Arne Boergel</dc:creator>
<dc:creator>Karine Lapouge</dc:creator>
<dc:creator>Kim Remans</dc:creator>
<dc:creator>David Agard</dc:creator>
<dc:creator>Mikhail Savitski</dc:creator>
<dc:creator>Athanasios Typas</dc:creator>
<dc:creator>Eugene V Koonin</dc:creator>
<dc:creator>Yue Feng</dc:creator>
<dc:creator>Joseph Bondy-Denomy</dc:creator>
<dc:date>2025-03-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Jumbo phage killer immune system targets early infection of nucleus-forming phages</dc:title>
<dc:identifier>pmid:40112800</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.016</dc:identifier>
</item>





























</channel>
</rss>